Drug Trial Radar · NCT07461220
Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Feb 18, 2026
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Integrative Research Laboratories ABIndustry
- Sponsor type
- Industry
- Collaborators
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- First posted
- Mar 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial's goal is to evaluate if the IRL757 is safe and has a good tolerability in participants with Parkinson's disease and experiencing apathy (a lack of interest or motivation). In addition, the trial is aiming to learn if IRL757 has effects on the symptoms of Parkinson's disease. Researchers will compare the effects of IRL757 to a placebo (a look-alike substance that contains no drug). Participants who fit the study criteria will be treated with the study drug (either the active drug IRL757 or placebo) for 12 weeks and will visit the clinic at 5 defined timepoints for check-ups and tests. A follow-up call after the end of treatment will be done 4 weeks after the last study drug intake.
Conditions
- PARKINSON DISEASE (Disorder)
- Apathy
- Safety
Interventions
IRL757Drug
IRL757 will be administered daily for 12 weeks. The study drug is available as capsules for oral administration.
PlaceboDrug
The study drug is administered daily for 12 weeks. The placebo is available in form of capsules to be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of IRL757 after repeated daily dosing for 12 weeks in participants with PD who have moderate to severe symptoms of apathyTime frame: From enrollment [signature of informed consent form] to end of study [4 weeks after last study drug administration]
- To evaluate the safety and tolerability of IRL757 after repeated daily dosing for 12 weeks in participants with PD who have moderate to severe symptoms of apathyTime frame: From enrollment [signature of informed consent form] to end of study [4 weeks after last study drug administration]
- To evaluate the safety and tolerability of IRL757 after repeated daily dosing for 12 weeks in participants with PD who have moderate to severe symptoms of apathyTime frame: From enrollment [signature of informed consent form] to end of study [4 weeks after last study drug administration]
Locations
14 sites in 4 countries. Site status is shown where the registry gives one.
Medical Center "Galileo" OOD
Pleven, Bulgaria · Recruiting
Medical Center Academica
Pleven, Bulgaria · Recruiting
First University Multiprofile Hospital for Active Treatment MHAT - Neurology Clinic
Sofia, Bulgaria · Recruiting
University Multiprofile Hospital for Active Treatment "Alexandrovska" EAD, Clinic of Neurological Diseases
Sofia, Bulgaria · Recruiting
Neurologie Berlin
Berlin, Germany · Recruiting
Universitaetsklinikum Carl Gustav Carus
Dresden, Germany · Withdrawn
Centrum Medyczne NEUROMED
Bydgoszcz, Poland · Recruiting
Neuro-Care sp. z o.o. sp. Komandytowa
Katowice, Poland · Recruiting
NeuroKlinika Prof. Andrzej Bogucki
Lodz, Poland · Recruiting
EuroMedis Sp. z o.o.
Szczecin, Poland · Recruiting
Centrum Medyczne NeuroProtect
Warsaw, Poland · Recruiting
Hospital de la Santa Creu i Sant Pau, Unidad de trastornos del movimiento
Barcelona, Spain · Recruiting
Hospital General Universitario de Elche
Elche, Spain · Not yet recruiting
Hospital Universitario Ramon y Cajal
Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.